Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Blood pressure measurement, Compulsions, Heart rate, Heart rate increased
Clinical narrative: Mental fogginess; high blood pressure; experience of tachycardia; high blood pressure and pulse; Extreme pain throughout entire spine; Psychotic event/  psychotic episode; Anxiety; compulsion; This is a spontaneous report from a contactable consumer (patient). A 58-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EP7533) via an unspecified route of administration in the left arm on 07Apr2021 at 12:00 as dose 1, single and the second dose of BNT162b2 (lot number: ER8731) via unspecified route of administration in the left arm on 28Apr2021 at 12:00 as dose 2, single both for COVID-19 immunization, at the age of 58-years-old. Medical history included chronic pain after trauma, asthma and cataract lens replacement. The patient was allergic to minor corn, peppers and had multiple environmental allergies. Patient was also allergic to cefalexin (CEPHALEXIN) and had problem with it. Concomitant medications included oxycodone taken at 15mg, morphine sulfate (MORPHINE SULPHATE) taken at 15mg and cannabis sativa (MARIJUANA) which was reported as medical marijuana (MMJ), all taken for unspecified indications from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 12:00, approximately 10 days after the first dose, the patient experienced anxiety and compulsion. On 21Apr2021, the patient experienced psychotic event that lasted for 3 days. On 25Apr2021, the following fourth day, the patient experienced extreme pain throughout entire spine that felt as if it was caused by an internal pressure. On 18May2021, patient still struggled with high blood pressure and pulse including experience of tachycardia, started on an unspecified date, during Doctor's appointment. On unspecified date, mental fogginess and anxiety was greater upon wakeup and lessened to almost decent before bedtime as of just a week prior the report. Patient saw magazine article referencing long-haulers possible link with antibody effect on some and felt this may be apropos with him as well. The patient could not feel that he could have coincidentally lost it yet with psychotic episode 14 days post first vaccination but, if it was antibody related it made sense to him. He was using diet in attempt to treat symptoms but did not share this information with others including doctors as yet. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, on 18May2021, the patient had been tested for COVID-19 and had antibody test and results were pending. The clinical outcome of the event psychotic event was resolved on 24Apr2021, while the clinical outcome of the other events was resolving at the time of this report.  Follow-Up (18Aug2021): Follow-up attempts are completed. No further information is expected.